Company Focus

CellTrion

Latest CellTrion News

Sandoz: stepping out from Novartis’ shadow
Generics
Swiss pharma Sandoz has spent less than a year charting its course as an independent company, but already it’s moving with the confidence of a seasoned player. Since separating from former parent Novartis in October 2023, the generics and biosimilars specialist has been working fast to reshape its identity—and its balance sheet.   22 July 2025


Latest News & Features of interest to CellTrion

Latest In Brief for CellTrion

Biotechnology
US biotech Genascence today announced the US Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA).   16 July 2025

Latest Relevant Ones To Watch News

Relevant Ones to Watch Companies

Reset all filters
Refine Search